Indication

Thyroid carcinoma

Thyroid carcinoma is a malignant neoplasm originating from the parenchymal cells of the thyroid gland, making it the most prevalent endocrine malignancy. Read more about Thyroid carcinoma

30 drugs 22 manufacturers

Advertisement

Drugs that treat it

Common Thyroid carcinoma therapies.

Showing 10–18 of 30 drugs

DOXORUBICIN HCL

ANTHRACYCLINE ANTIBIOTICS·OSTEOSARCOMA OF BONE·+19
SAGENT PHARMACE

DOXORUBICIN HCL

ANTHRACYCLINE ANTIBIOTICS·OSTEOSARCOMA OF BONE·+19
MYLAN INSTITUTI

DOXORUBICIN HCL

ANTHRACYCLINE ANTIBIOTICS·OSTEOSARCOMA OF BONE·+19
Laboratories Div

DOXORUBICIN HCL

ANTHRACYCLINE ANTIBIOTICS·OSTEOSARCOMA OF BONE·+19
MYLAN INSTITUTI

DOXORUBICIN HCL

ANTHRACYCLINE ANTIBIOTICS·OSTEOSARCOMA OF BONE·+19
APP/FRESENIUS K

DOXORUBICIN HCL

ANTHRACYCLINE ANTIBIOTICS·OSTEOSARCOMA OF BONE·+19
Actavis Pharma
Filter & compare in the drug finder →Opens the drug finder with Thyroid carcinoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Thyroid carcinoma.

Thyroid carcinoma is a malignant neoplasm originating from the parenchymal cells of the thyroid gland, making it the most prevalent endocrine malignancy.

It predominantly arises from thyroid follicular epithelial cells, categorized into well-differentiated forms such as papillary and follicular carcinomas, poorly differentiated variants, and undifferentiated anaplastic carcinoma, as well as neuroendocrine calcitonin-producing parafollicular C cells, which give rise to medullary thyroid carcinoma.

Patients frequently present with an asymptomatic thyroid nodule, though advanced or aggressive lesions can manifest with regional lymphadenopathy, hoarseness from recurrent laryngeal nerve invasion, dysphagia, or distant metastases.

Personalize your experience

Follow Thyroid carcinoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it